The potential of hybrid antibodies secreted by hybrid-hybridomas in tumour therapy

✍ Scribed by Mike Clark; Lisa Gilliland; Herman Waldmann

• Publisher: John Wiley and Sons
• Year: 1988
• Tongue: French
• Weight: 286 KB
• Volume: 41
• Category: Article
• ISSN: 0020-7136
• DOI: 10.1002/ijc.2910410706

✦ Synopsis

Using a simple method for the selection of hybrid cell growth from the cell fusion of pairs of existing hybridoma cell lines, 2 different hybrid-hybridoma cell lines were produced. Both hybrid-hybridomas secreted bi-specific antibody with similar specificity for human CD3 and for mouse Thy-I but in one case the parental antibody isotypes were both IgGlb and in the other case the CD3 antibody was 1gG2b and the anti-Thy-l antibody was IgG2,. In a model in vitro system both bi-specific antibodies were able to elicit potent cell killing of a Thy-I expressing mouse tumour cell line by human effector cell blasts. The cell blasts were generated from resting peripheral blood mononuclear cells using a mitogenic monoclonal antibody (MAb) (YTH361). The parental anti-Thy-I lgGzb but not the lgGzc antibody was also able to mediate cell killing by ADCC. This ADCC killing was inhibited by a MAb to the CD16 Fc receptor but the killing elicited by the bi-specific antibodies was not. Both mechanisms of tumour cell killing may be of great potential in human tumour therapy with MAbs.